Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mersana brings in $21mm with Series A round

Executive Summary

Mersana Therapeutics (formerly Nanopharma; cancer drugs) raised $21mm with an oversubscribed Series A round led by new investors Fidelity Biosciences and ProQuest Investments. Other first-time backer Rho Ventures was joined by returning shareholders PureTech Ventures (company co-founder), Cape Family Fund LLC, Harris & Harris Group, and Lansing Brown Investments.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies